Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Advancing to IND-enabling studies with multiple drug candidates
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated
